SYRS Syros Pharmaceuticals Inc.

13.43
+0.66  (5%)
Previous Close 12.77
Open 12.86
Price To book 4.49
Market Cap 353161135
Shares 26,296,436
Volume 99,857
Short Ratio 7.41
Av. Daily Volume 191,215

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016. Preliminary data due 4Q 2017.
SY-1425
Relapsed or refractory Acute myeloid leukemia (AML) and relapsed high-risk Myelodysplastic Syndrome (MDS) - cancer

Latest News

  1. Syros to Present at 29th Annual Piper Jaffray Healthcare Conference
  2. Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
  3. Syros to Present New Preclinical Data on SY-1365 and on Identification of Potential Drug Targets in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium
  4. Syros Announces Appointment of Jeremy P. Springhorn as Chief Business Officer
  5. Syros Reports Third Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
  6. Syros Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SYRS) : November 2, 2017
  7. Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 and New Preclinical Data on SY-1365 at ASH Annual Meeting
  8. Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SYRS-US : November 1, 2017
  9. Syros Presents New Preclinical PK and PD Data for SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
  10. Syros’ Drug Discovery Research in Immuno-Oncology Highlighted in Oral Presentation at American College of Surgeons Clinical Congress
  11. Syros Announces Oral Presentation Highlighting Its Drug Discovery Research in Immuno-Oncology at American College of Surgeons Clinical Congress
  12. Syros to Present New Preclinical PK and PD Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, at AACR-NCI-EORTC Conference
  13. Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML
  14. Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML
  15. Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARα Agonist, in Genomically Defined AML and MDS Patients
  16. Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference
  17. Syros Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SYRS-US : September 1, 2017
  18. Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress
  19. Syros Pharma Wins Orphan Designation From FDA
  20. Syros Receives FDA Orphan Drug Designation for SY-1425 for Treatment of AML